frα

FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα), exhibiting specific binding capabilities to cells expressing FRα and potential for in vivo tumor targeting. This peptide is utilized in research for tumor diagnosis and therapy.

Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer.

FRα-IN-1 (Compound 4) is a tumor-targeting agent that exhibits selective anti-cancer effects on cells expressing FRα and FRβ.

PDGFRα kinase inhibitor 1 is a highly selective inhibitor of type II PDGFRα kinase (PDGFRα and PDGFRβ) with IC50 values of 132 nM and 6115 nM, respectively.

PDGFRα FLT3-ITD-IN-3 (Compound 18d) is a potent inhibitor of PDGFRα (IC50: 0.153 μM) and FLT3 (IC50: 0.004 μM), with potential applications in the study of acute myeloid leukaemia or chronic eosinophilic leukaemia.

GFRα2 3-IN-1 (Compound 16) is a selective inhibitor of GFRα2 3, exhibiting IC50 values of 0.1 μM for GFRα2 and 0.2 μM for GFRα3. This compound is utilized in research related to pain and itch.

PDGFRα FLT3-ITD-IN-2 is a potent inhibitor of PDGFRα (IC50>20 μM) and FLT3 (IC50: 0.004 μM). PDGFRα FLT3-ITD-IN-2 has shown investigational potential in acute myeloid leukemia or chronic eosinophilic leukemia.

PDGFRα FLT3-ITD-IN-1 are potent inhibitors of PDGFRα FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively. PDGFRα FLT3-ITD-IN-1 exhibits investigational potential in acute myeloid leukemia or chronic eosinophilic leukemia.

Folic acid (Vitamin B9) is a vitamin B9 that is essential for the synthesis of DNA RNA and for the production and maintenance of new cells. Folic acid deficiency can lead to anemia, neural tube closure defects, tumors, aging, and other diseases.

EC-17 (disodium salt), a folate receptor alpha (FRα) targeting contrast agent, exhibits fluorescent properties within the visible light spectrum, characterized by peak excitation and emission wavelengths of 470 520 nm, respectively.

CBP-1018 is a peptide-drug conjugate (PDC) composed of a dual-targeting ligand for FRα TRPV6, linked to Monomethylauristatin E. It holds promise for research in the field of breast cancer.

Mirvetuximab (M9346A) is a novel folate receptor α (FRα) monoclonal antibody targeting anti-FOLR1 (folate receptor 1). Mirvetuximab soravtansine is often conjugated with platinum compounds or other compounds to form antibody-drug conjugates for the treatment of ovarian cancer and other FRα-positive cancers.

CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) with MMAE, targeting folate receptor (FRα) and TRPV6. It exhibits high binding affinity to FRα and low affinity to TRPV6. CBP-1008 shows antitumor activity and can be utilized for research in advanced solid tumors such as colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma, and follicular dendritic cell sarcoma.

EC17 is a FITC conjugated folic acid, also known as Folate-FITC. It also acts as an FRα-targeting agent that fluoresces at 500nm. EC17 is a conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic acti

Farletuzumab (MORAb-003) is a humanized monoclonal antibody with a high affinity for folate receptor-α (FRα), acting as a potent inhibitor of FRα and impeding the growth of cells that overexpress this receptor, making it useful for cancer research.

LY309887 is a potent inhibitor of glycinamide ribonucleotide formyltransferase (Ki: 6.5 nM) with antitumor activity.